Deleting an Alzheimer’s-linked gene called CASS4 in mice impairs the ability of brain immune cells to surround and compress toxic protein plaques, according to new research published in Journal of Experimental Medicine.
Without this gene, mice bred to develop Alzheimer’s-like pathology accumulated larger, looser plaques, suffered worse nerve-fiber damage, and struggled to adapt when a learned task changed. The findings indicate that CASS4 helps immune cells maintain the internal anchoring machinery needed to move toward brain damage and contain harmful deposits.
A cancer-linked gene inside the brain’s immune cells
Alzheimer’s disease is a progressive neurological condition that erodes memory and thinking, marked in the brain by clumps of amyloid-beta protein and tangled tau fibers. Genetic research increasingly points to microglia, the resident immune cells stationed inside the brain and spinal cord that sweep branching arms through tissue to watch for injury or disease. Human brain mapping, including an analysis of 3.4 million individual brain cells, suggests that after a gradual early loss of certain inhibitory neurons, Alzheimer’s shifts into a rapid phase of widespread inflammation, microglial changes, and accelerating plaque buildup.
Many inherited DNA variations tied to late-onset Alzheimer’s sit near genes active mainly in microglia. One prominent example is CASS4, first linked to Alzheimer’s risk in a 2013 genetic meta-analysis of more than 74,000 people. Microglia are virtually the only resident brain cells that switch this gene on, yet what CASS4 does in the brain has remained largely unknown.
Don’t miss the next big psychology finding
Every morning, PsyPost sends a short briefing on the most interesting new peer-reviewed research in psychology and neuroscience.
CASS4 belongs to a family of scaffold proteins, which have no enzyme activity of their own and instead act as docking stations where signaling molecules assemble. Studies of tumor cells show that CASS4 and its relatives organize focal adhesions, microscopic anchor points made of structural actin fibers at a cell’s outer membrane that let the cell grip surfaces, extend projections, and crawl. Because earlier work focused on cancer migration, the authors of a 2014 review argued that although CASS4 was known to guide cell movement, its function in the brain and in Alzheimer’s remained unexplained.
In parallel, neuroscientists found that physical gripping forces are central to how microglia limit amyloid-beta damage. Rather than only swallowing debris, microglia swarm plaques to form a tight cellular barrier, and a 2015 brain-imaging study in mice showed that this shield compacts loose, toxic amyloid threads into dense, rounded bundles that cause less harm to nearby nerve fibers. Connecting these threads, lead author Adeline E. Walsh, senior author John R. Lukens, and their colleagues in the Lukens Lab at the University of Virginia tested whether losing CASS4 disrupts microglial focal adhesions and weakens plaque containment.
“Despite CASS4 being recently identified as a major risk gene for Alzheimer’s disease, little is known about how it functions to influence brain health and disease,” Lukens, the William R. Kenan Jr. professor of neuroscience and Harrison distinguished teaching professor in the university’s Center for Brain Immunology and Glia, told PsyPost. “Findings presented in our recently published paper sought to bridge this gap in knowledge.”
Larger plaques, nerve injury, and reduced mental flexibility
The researchers used gene editing to generate mice lacking CASS4 throughout the body and bred them with an Alzheimer’s mouse model carrying five human mutations that trigger rapid amyloid-beta buildup. The team posted their sequencing datasets, source data, and analysis code publicly online.
To keep plaque development consistent across animals, all cohorts consisted of female mice, which develop amyloid pathology faster and more uniformly than males in this strain. Every mouse also inherited the Alzheimer’s mutations from its father, controlling for recent evidence that plaque burden varies depending on which parent passes the genes down.
At five months of age, the scientists stained slices of the hippocampus, a memory hub, and the outer cerebral cortex with a fluorescent plaque dye, imaging 9 to 12 fields per region per mouse. Compared with Alzheimer’s-model littermates with intact CASS4, mice missing the gene had more numerous and larger plaques in both regions.
Microscopy also pointed to worse nerve-fiber injury near those deposits. Mice lacking CASS4 had greater hippocampal buildup of amyloid precursor protein, which is distinct from the amyloid-beta fragments in extracellular plaques and instead serves as a standard marker of neuronal damage when it pools inside swollen nerve fibers. They also showed elevated levels in both the hippocampus and cortex of ATG9, a cellular recycling protein that similarly collects inside unhealthy axons.
To examine gene activity across cell types, the team pooled hippocampi from six five-month-old mice per group and sequenced RNA from 33,985 cell nuclei across 10 cell populations. Deleting CASS4 did not alter cell-type proportions and confirmed that microglia are the main resident brain cells expressing the gene.
Even so, nearly 3,000 genes shifted in excitatory neurons, which send activating signals, with increased expression of genes and pathways tied to spatial working memory and motor learning. Over 200 genes changed in inhibitory neurons, which quiet brain circuits, including lower expression of genes that maintain neural circuitry.
The team next assessed cognition at four months of age in the Morris water maze, training 10 Alzheimer’s-model mice per group over four days to find a submerged platform in opaque water using wall cues. Following a fifth-day memory probe with the platform removed, the researchers relocated the platform to the opposite quadrant for four more training days to test cognitive flexibility, the ability to abandon an old rule and adapt to a change.
During initial training and the first memory probe, differences between the groups were not statistically significant, indicating intact spatial learning and recall. Once the platform moved, however, CASS4-deficient Alzheimer’s mice swam farther from the new location and lingered in the old quadrant, whereas littermates with CASS4 adjusted to the new target.
Differences in swim speed, distance traveled, and anxiety-like behaviors in separate maze tests were not statistically significant, ruling out sluggishness or fear as likely explanations. In a control test of 14 CASS4-deficient and 12 normal mice without Alzheimer’s mutations, deleting CASS4 caused no detectable deficits, indicating that impaired cognitive flexibility arose specifically alongside amyloid pathology.
Microglia lose their grip around amyloid plaques
To learn why plaques caused worse damage without CASS4, the scientists examined microglia at five months using microscopy and flow cytometry, which sorts cells with lasers. Differences between groups were not statistically significant for microglial counts, cell division, activation markers, or the share of microglia engulfing fluorescently tagged amyloid-beta over three hours in six to seven mice per group. Single-nucleus RNA sequencing backed up those imaging results, showing equivalent proportions of resting homeostatic microglia and protective disease-associated microglia in both groups.
Instead, the defect involved physical contact at plaque borders. CASS4-deficient mice had markedly fewer microglial branches positioned right next to plaques, and their deposits were less dense, less spherical, and surrounded by a higher proportion of loose, diffuse amyloid-beta relative to compact cores in both the hippocampus and cortex.
Deleting a gene across the entire body from conception leaves open whether developmental changes or immune cells outside the brain contributed to the results. To isolate the role of brain-resident microglia, the researchers bred a conditional mouse line in which CASS4 could be switched off later in life using a drug-activated enzyme in microglia and related immune cells.
Young Alzheimer’s-model mice ate food laced with the drug tamoxifen for two weeks after weaning to trigger that deletion, then returned to regular chow. Over the following months, short-lived immune cells in the bloodstream were naturally replaced by new cells with intact CASS4, whereas long-lived microglia in the brain remained CASS4-deficient.
At five months, mice lacking CASS4 only in microglia matched the full-body knockouts, showing more and larger hippocampal plaques, poorly compacted deposits, and greater nerve-fiber damage alongside unchanged overall microglial volume. Because neurons do not produce CASS4, the authors suggest that poor microglial plaque containment exposes brain tissue to looser, more toxic amyloid-beta that harms nearby nerve cells.
Disrupted focal adhesions and a blunted injury response
Looking inside microglia, hippocampal RNA sequencing showed lower activity in gene pathways that build contractile actin filaments, the internal cables cells use to pull and move. Because focal adhesions are controlled largely by phosphorylation, the chemical tags that switch signaling proteins on or off, the team isolated brain microglia from five mice per group and screened 1,318 protein sites across two antibody arrays.
Averaging the two arrays without formal statistical testing, the researchers flagged 93 altered proteins using an asymmetric cutoff that required a steep jump to count an increase (an average log fold change above 1.4) but a much smaller dip to count a decrease (below -0.4). Roughly 17 percent of those 93 proteins belonged to focal adhesion pathways.
Under those criteria, CASS4-deficient microglia had fewer activation tags on downstream proteins that drive cell extensions and on an activating site of the receptor for macrophage colony-stimulating factor, a signal that prompts immune cells to migrate. Several upstream surface adhesion proteins showed increased tagging, which the authors propose may reflect a cellular effort to compensate for the downstream block.
Follow-up experiments tested focal adhesions and movement directly. Cultured microglia from newborn CASS4-deficient mice formed smaller patches of paxillin, a core focal adhesion protein, and bone marrow macrophages from five CASS4-deficient mice crawled more slowly across a scratched gap over 12 hours than cells from five normal mice when stimulated with migration-triggering proteins.
Finally, the scientists implanted tiny glass windows into the skulls of four to five live mice per group with fluorescent microglia and created a microscopic laser burn in the cortex while imaging for 40 minutes. Normal microglia rapidly extended branches onto the injury, whereas CASS4-deficient microglia mounted a blunted response.
The starkness of that live-imaging result stood out to the team. “Surprisingly, the microglia that were lacking CASS4 barely responded to the laser injury at all, suggesting that CASS4 plays a key role in this very important microglial function,” Lukens noted.
“This work suggests that therapeutics that promote CASS4 function in microglia could provide a novel strategy to limit Alzheimer’s disease progression,” Lukens said. “Moreover, our work suggests that the downregulation of CASS4 expression could also potentially serve as a much-needed biomarker to detect the early stages of Alzheimer’s disease.”
In medicine, a biomarker is a measurable biological indicator that can signal a condition before major symptoms take hold, in this case a drop in CASS4 gene activity. Together with the molecular data, the authors suggest that supporting CASS4 and related focal adhesion pathways might help keep microglial barriers intact.
Study caveats and future directions beyond Alzheimer’s
There are a few caveats to keep in mind. All experiments took place in mice and cultured cells, using an aggressive amyloid-producing mouse strain that lacks tau tangles and does not mirror the decades-long course of human late-onset Alzheimer’s disease. Completely deleting CASS4 is also a much starker change than the single-letter DNA variations linked to human risk, and as the authors note, future studies must test those human variants directly.
In addition, the Alzheimer’s pathology and behavioral experiments used only female mice to keep plaque timing consistent, leaving open whether CASS4 loss affects males identically. The dish-based wound-healing assays also used bone marrow macrophages as a stand-in for microglia, though the live laser-injury experiments confirmed that microglia inside intact brains similarly struggled to mobilize without CASS4.
“Our recent findings indicate that CASS4 is a pivotal regulator of microglial responses in the brain,” Lukens added. “Given that microglia have also been shown to be major players in multiple other neurological disease settings, we are particularly interested in investigating if CASS4 also plays important roles in other neurodegenerative diseases such as Parkinson’s, ALS, and multiple sclerosis. In addition, we are also eager to work with collaborators at the UVa Manning Institute to develop first-in-class CASS4-targeting drugs that can be pursued in future clinical trials to treat neurological disorders.”
Unlike existing Alzheimer’s drugs that primarily remove amyloid plaques directly, a first-in-class CASS4 therapy would aim to work through a new biological mechanism by strengthening the immune cells involved in conditions ranging from Alzheimer’s to amyotrophic lateral sclerosis, the motor-neuron disease commonly known as ALS.
The study, “Alzheimer’s genetic risk factor CASS4 controls microglial focal adhesion biology and amyloidosis,” was authored by Adeline E. Walsh, Benjamin A. Davis, Joshua D. Samuels, William A. Mills III, Jessica M. Thanos, Alexis M. Johnson, Katelyn A. Moore, Michael A. Puchalski, Eric J. Steacy, Benjamin W. Wendell, Amélie Daugherty-Lopès, Adrian A. Shimpi, Ukpong B. Eyo, and John R. Lukens.